Anx-131 May 2026

For decades, the treatment of Generalized Anxiety Disorder (GAD) and post-traumatic stress disorder (PTSD) has been a pharmacological balancing act. On one side, you have benzodiazepines (Xanax, Valium)—effective but highly addictive, with tolerance and withdrawal risks. On the other, you have SSRIs (Zoloft, Prozac)—safe but slow-acting, with side effects that often make patients quit before they work.

But what if there was a third path? Enter , a novel, oral, negative allosteric modulator (NAM) of the GABAA receptor. ANX-131

Wait—a negative modulator for anxiety ? That sounds backwards. Here is the clever biophysics: The GABA-A receptor has many subunits. ANX-131 is highly selective for the α4β3δ subunit. For decades, the treatment of Generalized Anxiety Disorder

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice. ANX-131 is an investigational drug that has not been approved by the FDA or other global regulatory bodies. By [Your Name/Handle] But what if there was a third path

ANX-131 is a . It gently reduces the overactive tonic current caused by these δ-subunits, allowing the brain’s natural phasic (on-demand) inhibition (via α1 and α2 subunits) to work properly again.